Study of dabrafenib plus trametinib in adults with BRAF V600 mutant stage III-IV melanoma
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
Most Recent Events
- 28 Oct 2022 New trial record
- 13 Sep 2022 Results (n=49; At data cutoff 22 Mar 2022) presented at the 47th European Society for Medical Oncology Congress.